When does Nplate’s (romiplostim) patent protection end?
Nplate (romiplostim) is a biologic product, so its “patent end date” depends on which specific patent family you mean (e.g., composition-of-matter, formulation/device, or method-of-use) and which country’s laws apply. Patent expirations are also often followed by regulatory exclusivity periods that can further delay generic or biosimilar entry.
The provided information does not include Nplate’s specific patent expiration date(s), country, or patent numbers, so the exact end date can’t be determined from this prompt alone.
Which patent end date matters for biosimilar/competition timing?
For drugs like Nplate, the launch timing of a biosimilar usually hinges on:
- the expiration of the relevant Orange Book-style listed patents (where applicable), and
- any additional exclusivity granted under the biologics regulations,
- plus any patent litigation stay/appeals that can extend timelines.
To pinpoint the actual “end date,” you typically need the jurisdiction (e.g., US vs EU vs UK vs Canada) and the specific patent(s) listed for Nplate.
What should you look up to get the exact Nplate end date?
Search using:
- Product name: “Nplate” + “romiplostim”
- Jurisdiction: “US patent” (FDA/Biologics), “EP patent” (EPO), etc.
- Patent identifiers: the specific publication/patent numbers tied to Nplate
If you share the country (and ideally whether you mean “US patents,” “EU patents,” or a specific listed patent number), I can help you narrow down the exact patent end date(s) that correspond to Nplate’s protection timeline.
Quick clarifying questions
1) Which country’s patent end date do you want (US, EU/EP, UK, etc.)?
2) Do you mean the end of the last relevant patent for biosimilar entry, or a particular patent family/number?